The growing concern over antimicrobial resistance (AMR) has taken center stage with a recent multi-country study revealing a stark reality: WHO-recommended antibiotics for neonatal sepsis are effective in only a quarter of cases in low- and middle-income countries (LMICs). This eye-opening finding, presented at ESCMID Global 2026, underscores the urgent need to address the evolving landscape of antibiotic resistance.
Neonatal sepsis, a critical infection affecting newborns within their first month of life, remains a leading cause of mortality worldwide. The World Health Organization (WHO) currently recommends a combination of ampicillin and gentamicin as the first line of defense against this deadly infection. However, the study, conducted across 13 neonatal units in Pakistan, Bangladesh, and Nigeria, highlights the limitations of these recommendations when applied to LMIC settings.
The BARNARDS II study, led by researchers from the University of Oxford, sheds light on the challenges of implementing global treatment guidelines in diverse environments. With an initial treatment regimen varying widely and typically involving one to three antimicrobials, the study found that only 40 neonates received the WHO-recommended combination. Out of 5,012 culture-confirmed cases, the effectiveness of the recommended antibiotics was limited, with high levels of AMR observed.
Lead author Dr. Kathryn Thomson emphasizes the concerning rates of AMR, stating that the substantial burden makes identifying consistently effective empirical antibiotic regimens extremely challenging. In these settings, the locally prevalent, highly resistant pathogens render the WHO-recommended therapy less effective.
Dr. Thomson further explains that the deviation from guidelines is clinically understandable, reflecting an adaptation to local resistance patterns rather than poor adherence. This adaptation highlights the complexity of applying global recommendations to diverse healthcare environments.
The study's findings have broader implications for neonatal care. Principal investigator Professor Tim Walsh emphasizes the need for a shift towards locally informed empirical treatment strategies, enhanced diagnostics, and continued AMR surveillance. He concludes that improving neonatal outcomes requires a comprehensive approach, including antimicrobial stewardship and sustainable access to effective antibiotics, supported by long-term policy commitment and investment.
In my opinion, this study serves as a wake-up call, urging us to reevaluate our global approach to antibiotic guidelines. The one-size-fits-all model is clearly inadequate, and we must embrace a more nuanced and context-specific strategy. By understanding the unique challenges faced by LMICs, we can develop targeted interventions to combat AMR and improve neonatal survival rates.
As we reflect on the study's implications, it becomes evident that a collaborative effort is needed to address this global health crisis. By combining local expertise with global resources, we can work towards a future where neonatal sepsis is effectively managed, regardless of geographical boundaries.
